Personalized medicine support system : resolving conflict in allocation to risk groups and predicting patient molecular response to targeted therapy by Banjar, H. et al.
PUBLISHED VERSION 
 
Haneen Banjar, David Adelson, Fred Brown, and Tamara Leclercq 
Personalized medicine support system : resolving conflict in allocation to risk groups 
and predicting patient molecular response to targeted therapy 
Health Informatics - An International Journal, 2017; 6(2):1-21 
 
 
This is an open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, provided 
the original author(s) or licensor are credited and that the original publication in this journal is 
cited, in accordance with accepted academic practice. No use, distribution or reproduction is 
permitted which does not comply with these terms. 

























Email confirmation CC BY license 24 Mar 2018. 
http://creativecommons.org/licenses/by/4.0/ 
       
 
26 March 2018 
Health Informatics - An International Journal (HIIJ) Vol.6, No.2, May 2017 
DOI: 10.5121/hiij.2017.6201                                                                                                                                               1  
 
PERSONALIZED MEDICINE SUPPORT SYSTEM: 
RESOLVING CONFLICT IN ALLOCATION TO RISK 
GROUPS AND PREDICTING PATIENT MOLECULAR 
RESPONSE TO TARGETED THERAPY 
 
Haneen Banjar1, 2, David Adelson3, Fred Brown2and Tamara Leclercq4 
 
1School of Computer Science, University of Adelaide, Adelaide, Australia. 
2The Department of Computer Science, King Abdul Aziz University, Jeddah, Saudi 
Arabia. 
3School of Molecular and Biomedical Science, University of Adelaide, Adelaide, 
Australia 
4Cancer Theme, South Australian Health and Medical Research Institute (SAHMRI), 




Treatment management in cancer patients is largely based on the use of a standardized set of predictive 
and prognostic factors. The former are used to evaluate specific clinical interventions, and they can be 
useful for selecting treatments because they directly predict the response to a treatment. The latter are used 
to evaluate a patient’s overall outcomes, and can be used to identify the risks or recurrence of a disease. 
Current intelligent systems can be a solution for transferring advancements in molecular biology into 
practice, especially for predicting the molecular response to molecular targeted therapy and the prognosis 
of risk groups in cancer medicine. This framework primarily focuses on the importance of integrating 
domain knowledge in predictive and prognostic models for personalized treatment. Our personalized 
medicine support system provides the needed support in complex decisions and can be incorporated into a 
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1.1 Personalized medicine 
 
Personalized medicine could be used to establish molecular characteristics that are unique to an 
individual, usually because of varying genetic makeup. With this, doctors can offer a more 
specific diagnosis andeffective treatment protocol for an individual’s disease. In clinical decision-
making, personalized medicine is used to make decisions that maximize the outcomes and 
minimize the side-effects of treatment by using available knowledge about an individual [1]. 
Many studies have focused on personalized care, and its scope of application has increased 
because it leads to more successful outcomes and minimizes the chances of adverse reactions 
associated with certain treatment plans. Personalized medicine involves classifying individual 
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patients into sub-populations that pose unique reactions, susceptibilities or general responses to 
particular treatments to determine the best treatment approaches for every patient [2]. 
 
Personalized medicine offers high precision, and it has attracted much interest because it affords 
advantages such as improved healthcare and reduced need for the development of new medicines 
[3]. Personalized medicine also helps to minimize unnecessary costs by reducing both the time 
spent on treatment and the failure rates during clinical trials [4].Economic value increases when 
caregivers implement personalized medicine in healthcare, because it helps to reduce the 
unnecessary use of resources.  
 
Traditional personalized medicine contrasts with modern personalized medicine in how suitable 
therapies are identified for patients. In the former, a diagnosis is predicted based on a patient’s 
family history, social circumstances, environment and lifestyle.  In the latter,this prediction is 
based on a patient’s genetic makeup [2]. Medical researchers continue to emphasize that their 
studies are updated with the most effective treatment protocols used to treat cancer patients. 
However, different patients show different responses to the same therapy. For example, when 
subjected to the same therapeutic protocol, the clinical outcomes of two patients may be different 
in terms of response and survival[5]. This undesirable situation could potentially be avoided by 
improving predictive assays to predict an individual’s response to therapy at diagnosis. Indeed, 
during recent years, studies have tried to individualize medicine by using predictive factors to 
determine initial treatments. Many studies have used different techniques to investigate factors 
that could affect drug responses. Sioud et al. [6]noted that individualized treatment algorithms 
could depend on integrating the factors that influence drug responses. For example, studying a 
single biomarker as a predictor could indicate the response before treatment and predict the risk to 
the individual [7]. Another approach involves predicting a drug reaction in terms of toxicity or 
resistance by using an individual’s genotype data and clinical data to improve the individual’s 
care [8].Inpharmacogenetics, an individual’s response to a specific therapy is studied based on 
his/her genotype information. The European Science Foundation established a roadmap for 
developing personalized medicine [9] and stated that to build a predictive model, data for 
individualized treatment options were needed, and response variations in different sub-
populations of patients and diseases needed to be stored. Fagan and Shortliffe[10] noted the 
power of using a computer to (1) analyze the combination of biological and clinical data, which 
are disparate data sources, and (2) discover the relationships amongst complex database schema 
that store medical records. 
 
As treatment optimization is an important medical advancement, many computer science 
researchers have focused on predicting the response to treatment [11]. Indeed, many studies have 
reported on the development of a prognostic or predictive model that could predict the side-
effects of drugs [12-15]; such models use intelligent techniques to address medical issues. This 
gives researchers a new way of applying the strength of machine-learning techniques to real 
medical problems. Current intelligent systems could potentially aid in transferring advancements 
in molecular biology into practice, especially for predicting molecular response to targeted 
therapy and the prognosis of patients (in different risk groups) in cancer medicine.  
 
1.2 Clinical Decision Support System 
 
A clinical decision support system (CDSS) is a type of decision support system that analyses 
medical data to assist healthcare providers in making appropriate and automated clinical decisions 
[16]. Constructing a CDSS requires substantial modeling activity by selecting relevant medical 
data and a problem-solving strategy to reach appropriate conclusions. For the analysis, 
collaboration with clinical experts is needed to model relevant application areas. Based on the 
nature of this collaboration, there are two types of CDSSs: knowledge-based CDSS and non-
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knowledge-based CDSS [17]. A key research area in CDSS is the advancement and application of 
knowledge-based systems because of the usability of expressing various types of human 
knowledge in an intelligent system. Combining expert knowledge and discovered knowledge in 
the medical domain maximizes the qualities that they have separately [18]. There are also three 
classificationsfor CDSS: information management, situational awareness and patient-specific[19]. 
Information management uses buttonsfor obtaining up to date information; situational awareness 
uses alerts or dashboard for obtaining information; and patient-specific may be implemented for 
different purposes such as diagnosis, treatment management or recommendation [20]. Identifying 
the key needs and functional requirements and determining how to evaluate the system are 
interrelated issues in designing and implementinga CDSS [21]. Understanding a medical problem 
and its domain are also primary requirements for implementinga knowledge-based CDSS. 
Additional requirementsinclude knowing who will deliver the information from the CDSS and 
how the CDSS can provide support starting from diagnosis and selecting treatment to monitor and 
follow-up the outcomes. 
 
In the last decade, information technology has been introduced to improve clinical practice [22]. 
Information systems make data storage and data retrieval easier. This enhances the use of CDSS 
in clinical practice, and it helps to prevent errors and deliver needed information at the time of 
request. The development of CDSS has been influenced by the purpose of use and advancements 
in medical technology. Researches are motivated by the concept of personalized medicine, and 
they have introduced personalized modeling for developing CDSSs based on the information of 
individual patients, such as clinical and molecular information [23]. 
 
Automatic knowledge acquisition techniques have also attracted much research interest. 
Knowledge acquisition is the first step in building a knowledge base, and it requires techniques to 
drive knowledge. Data mining is widely used for knowledge acquisition,and the knowledge 
discovery process is used as a schema to automatically discover knowledge, which can include 
the shape of patterns or associations among data features and rules. This process generally 
includes four steps: problem understanding and data understanding, data pre-processing, model 
induction, and post-processing [24]. A recent review [25]discussed knowledge discovery in 
medicine. In this review, the authors identified the primary studies in medical research 
applications through data mining techniques. They found that the focus has moved to the medical 
domain more than in the past and that the use of hybrid systems is the future for solving complex 
problems in medicine. Complex problems in the medical domain began with the success of 
sequencing the human genome.  The morenew biological information was made available, the 
greater the demand to build intelligent systems that can utilizethis information. Intelligent systems 
such as CDSSs should be adaptive to any new information made available on an ongoing basis. 
From adaptive behavior, evolving systems have been introduced to use particularly intelligent 
systems and online learning algorithms for knowledge acquisition from data and for realizing 
advanced model structures in data mining tasks and parameters [26]. 
 
1.3 Knowledge-based Systems  
 
Researchers have also focused on the integration of knowledge from multiple sources, which is a 
key issue in many areas such as collaborative knowledge systems, group decisions and distributed 
expert systems, where knowledge from multiple sources is often contradictory. We need to be 
comfortable with a wide range of knowledge resources that will help clinicians in decision-
making, as a conflict between two sources, rules, or decision-makers is often observed in real 
cases. 
 
Conflicts in knowledge-based systems can be divided into three types: schema conflicts, data 
conflicts, and knowledge conflicts [27]. Schema conflicts can arise from the use of different 
schema definitions such as tables or objects. Data conflicts may ariseowing to incorrect data. A 
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study compared the ability of several techniques to reduce inconsistency in data [28]. Knowledge 
conflict may arise when multiple sources of knowledge are integrated. Knowledge conflict is a 
major issue in distributed artificial intelligence systems [29]. Adrian et al.[30] defined 
contradiction as an ‘inability for all conceived statements or beliefs to be simultaneously true’. A 
contradiction may also be referred to as an inconsistency. For instance, there may be a 
contradiction between sentences such that one sentence must be true and the other must be false. 
 
This common situation requires some advanced methodologies to resolve the conflict. One active 
research direction is the use of the multiple criteria decision analysis (MCDA) approach [31, 32]. 
This technique is developed to capture the relative preference information of decision-makers 
who are involved in a conflict. There is a prescriptive approach based on progressive preferential 
knowledge [33]. This approach resolves the conflicts of rules in a knowledge-based system by 
using decision analysis techniques, where incorporating a user’s preference in judgment about the 
rules is important. These methods for conflict resolution in a rule-based system always need 
toincorporate a user’s preferences in some specific problem domain that is very difficult to obtain 
in the medical domain. Experts’ opinions, including preferences, are often vague and difficult to 
estimate using exact numerical values. Noor-E-Alam et al. [34] developed a framework that used 
qualitative form as a linguistic term to represent experts’ opinions. Their approach aimed to use 
multi-expert multicriteria decision making (ME-MCDM) to reach a single decision by integrating 
multiple experts’ opinions. The linguistic truth value (LTV) can be used to judge alternatives for 
ME-MCDM. Two suitable algorithms are used to handle conflict aggregation: possibility measure 
and averaging conflict aggregation. Junming et al. [35] designed a framework using fuzzy case 
base reasoning for conflict resolution. This approach aimed to find similar cases in the resources 
and to retrieve the information that resolved the problem. They defined linguistic variables for 
comparing the retrieved information. Sometimes, it is important to measure the inconsistency; 
based on the results, the researcher can decide what to do with it. For example, one can measure 
the conflict and agreement between two knowledge bases [36] or the inconsistency of knowledge 
bases [37-41].Some studies used machine learning techniques to resolve conflicts. Recent studies 
on multi-agent systems aimed to resolve conflicts by combining machine learning techniques 
such as Bayesian network, case-based reasoning and expert systems [42]. This study 
demonstrated that ‘the choice of the specific technique for a given domain depends on the 
specification of the domain’. 
 
1.4 Medical Data and Knowledge 
 
Clinical trials are usually conducted in a series of phases. Each clinical trial phase aims to answer 
a specific research question. Phase I is designed to test a new treatment in a small population and 
to identify side-effects and treatment safety. In Phase II, researchers test the drug on a larger 
population (several hundred individuals) and evaluate its efficacy and safety. In phase III, the trial 
is designed to study the efficacy in a population of several hundred to a thousand individuals. 
Phase IV is designed to monitor the drug in the general population after it is marketed[43]. Late 
phases of the clinical trials,such as phases II, III and IV, are considered important sources of 
information that can be used to build mathematical models. There is a rapid increase in the 
number of electronic medical research databases that provide an opportunity for researchers to 
reuse medical data to create mathematical models. To access the clinical trial data, the NCI[44]is 
a US agency that lists ongoing clinical trials of molecular targeted therapies. Investigators within 
hospitals and medical centers conduct most of the NCI-supported trials. The NCI provides the full 
trial description and the name of the principal investigator for these studies. Researchers can 
contact the investigators and collaborate with them. 
 
Clinical trial data may be biasedin several aspects: sampling, referral, selection, method and 
clinical spectrum. The clinical trial may use sampling methods, sample size and inclusion and 
exclusion criteria. Another aspect is the referral bias, where a specialist refers patientsand thus the 
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data represents pre-selected patients who have high prevalence of a disease. The selection bias is 
clear when the clinical trial data includes a group based on various demographics. Data may be 
collected using different measurements, leading to different precisions and specifications. Finally, 
the clinical spectrum bias is represented in the patient’s record, which may show other medical 
problems with the disease [24]. For instance, Saussele and Pfirrmann[45] reported clinical trials 
of chronic myeloid leukemia (CML). They noted several issues that may challenge the reuse of a 
clinical trial data. According to Saussele and Pfirrmann, the definition of ‘remission’varies in 
clinical trials depending on the major molecular response (MMR) or complete cytogenetic 
response (CCR). In addition, clinical trials use different primary endpoints such as 12-month 
MMR or 12-month CCR to determine the treatment success. 
 
From patient care to patient administration, electronic health records (EHR) are reused in many 
studies to answer specific research questions [46-49]. Cases were matched with enquires based on 
obtained research criteria for patient inclusion, and a dataset of many matches can be generated 
for analysis. The EHR may include sparse data or missing values, as some patients may not seek 
frequent care. The EHR quality would likely impact the bias in the research finding or the 
modeling performance. Thederivation of key variables is also an important aspect when dealing 
with EHR, as the values may be recorded in different ways in different systems. This arises 
because of varying definitions between sources. The data quality and correct values of derived 
key variables will concern researchers,and many algorithms can be investigated during pre-
processing to improve the data quality,thereby providing reliable results [50]. 
 
The reuse of medical data and knowledge for cancer treatment requires advanced computational 
methods such as intelligent systems. Using multiple sources of data and knowledge for 
personalized medicine support systemswillcreatelarge amounts of information to deal with for 
evaluating therapies and potential diagnostic and prognostic markers.  
 
1.5 Predictive vs. Prognostic 
 
In oncology, predictive markers differ from prognostic markers [51, 52]. Predictive markers or 
factors used to evaluate specific clinical interventions, and they can be useful for selecting a 
treatment because they can directly predict the response to a treatment.Prognostic markers are 
used to evaluate a patient’s overall outcomes, and can be used to identify the risk or recurrence of 
a disease. By using advanced molecular technologies, many predictive and prognostic factors 
have been introduced in cancer medicine. Studying predictive molecular biology in detail is 
beyond the scope of this study;however, the list of possible predictive factors that have been 
published previously in separate studies such as clinical, pathological and molecular tests are the 
primary focus of our study. Based on the available data from medical research and clinical trials, 
one can create a list of possible predictive factors and prepare it for further investigation and also 
explore any relationship among the predictive factors.  
 
Several predictive and prognostic tests based on molecular biology have revolutionized cancer 
medicine. In our study, we propose collecting information about possible predictive factors and 
prognostic scores that are published in top-ranked medical journals such as Science, Medline and 
PubMed journals and in other publications indexed under keywords such as ‘prediction of 
molecular response’, ‘predict outcomes’, ‘prognostic model or score’, ‘prognostic indicators’ and 
‘predictive factors’. We propose communicating with several clinical trial investigators who are 
studying the efficiency of molecular targeted therapies and patient responses by using several 
predictive and prognostic factors for decision-making. Predictive factors that are regulated for use 
should be used. According to Mehta[51], predictive markers that are commercialized for 
decision-making should be reviewed by the FDA and be certified with adequate evidence. 
Official and ethical approvals on the reuse of medical research data should be obtained before 
establishing a list of predictive and prognostic factors from clinical trials. 
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1.6 Molecular Targeted Therapy 
 
Targeted cancer treatments are also called ‘molecularly targeted drugs’, ‘molecularly targeted 
therapy’ and so on [53]. Molecular targeted therapy is a sort of customized therapeutic treatment 
that aims to treat cancer by acting on unique mutations, overactive kinases, or protein anomalies 
that drive cancer development. Specifically, the medications used for targeted treatment are 
intended to act on a specific biochemical pathway vital to the survival of that specific cancer [54]. 
The FDA has approved numerous targeted cancer treatments to treat specific types of cancer [55]. 
Others are being examined in clinical trials (human testing), and numerous more are in preclinical 
testing (animal testing) [56].The National Cancer Institute (NCI) website lists multiple targeted 
therapies that have been approved for particular types of cancer[57]. For example, two targeted 
therapies named Bevacizumab (Avastin®)and Everolimus (Afinitor®)have been approved for 
treating brain cancer. Multiple targeted therapies are also available for leukaemia patients. To 
personalize targeted therapies, we need to determine the best therapeutic agent for an individual 
patient at the time of diagnosis. This can be done by studying the efficacy of each targeted 
therapy and developing a clinical trial. The NCI website provides a list of clinical trials of 
targeted therapies[57]. These trials are an important resource for shifting information from the 
laboratory to the implementation of personalized medicine. Developments in molecular 
technology will play a major role in realizing predictive, preventative and personalized medicine. 
Here, we also focus on the issue of how to reuse patients’ existing profiles, including personal 
molecular information gathered in clinical trials for resolving conflict in allocation to risk groups 
and predicting patient molecular response to targeted therapy. 
 
1.7 Research Motivations  
 
To benefit from molecular technology data for treatment and monitoring progress in cancer 
patients, implementing an intelligent system that integrates medical knowledge, identifies 
relevant features and suggests drugs or treatments for patientsas well as adapting a new source of 
data and knowledge to change, remains a future challenge. In this research, we focus on the 
following main question: ‘How can one develop a personalized medicine support system that 
allocates risk groups and predicts the molecular response tomolecular targeted therapy, where 
consistency in decisions is paramount?’ 
 
Therefore, previous studies have not considered improving knowledge-based CDSS that has a 
high-quality knowledge base to provide consistency in decisionsmade based on a patient’s 
molecular information for predicting his/her molecular response.The main objective of this 
framework is to build a personalized medicine support system as a knowledge-based system 
changes and evolves over time. This intelligent system will provide clinicians, patients and 
researchers with a platform to extract knowledge and to improve the personalized treatments of 
patients. Framework functions have not been considered in previous studies on personalized 
medicine,and they have also not been specifically applied in medical literature to the problem we 
are considering.Doing so will add substantial value to the work. Ageneric framework is presented 
that includes the following main sub-functions: (1) consistency test between scoring systems for 
predicting outcomes in cancer patients treated with molecular targeted therapy, (2) resolving 
conflicts in validated prognostic scores, (3) developing a predictive model to predict molecular 
response to molecular targeted therapy, (4) select relevant predictive factors for predicting 
molecular response to molecular targeted therapy, (5) derive a clinical prediction rule that uses 
clinical, molecular and cell count observations (these predictive factors were collected atdiagnosis 
and categorized based on domain knowledge) and (6) adaptive methods that can evolve 
knowledge-based systems over time. 
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2. PROPOSED FRAMEWORK 
 
In this section, the system overview ispresented, stages of implementing a personalized medicine 
support system are discussed and the system structure is described in detail. 
 
2.1 Overview of Personalized Medicine Support System 
 
Patient treatment has become increasingly difficult in recent years as various molecular targeted 
treatment options have become available. Clinicians aim to treat individual cancer patients with 
the most appropriate therapy. The ultimate challenge is to decide the most appropriate treatment 
strategy for an individual patient. To facilitate this, the disease assessment of an individual patient 
in terms of risk profile and molecular response to initial molecular targeted treatment should be 
determined. In prognostic models, low-risk patientsare preferentially treated with the least toxic 
and safest therapeutic options. These patients’ molecular responsesare predicted using the 
predictive model built for the initial molecular targeted treatment. In higher-risk patients, higher-
toxicity or combination treatment options may be favoured. High-risk patients or those who fail to 
respond to initial therapy will benefit from this approach as their response should bepredicted, 
thereby preventing resistance and/or intolerance to therapy, that may have otherwise ensued. 
Thus, this system aims to enhance individual disease and treatment management. 
A personalized support system is designed for selecting patient therapy. Reused medical research 
data (clinical trial data) and prior knowledge collected from literature are used with advanced 
computational techniques to allocate risk groups and predict patients’ molecular response to 
molecular targeted therapy at diagnosis. The personalized medicine support system uses two 
models as a guide for treatment selection (Figure 1):(1) prognostic model and (2) predictive 
model. 
 
Figure1. Process flow of personalized medicine support system 
 
 
2.1.1 Prognostic Model 
 
The prognostic model uses four data mining processes: problem understanding and data 
understanding, data pre-processing, model development and post-processing. In medicine, it is 
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important to investigate current validated prognostic factors and score systems that are used to 
stratify cancer patients according to risk profile to ensure appropriate treatment. Historically, 
prognostication has seen rapid developments, and various scoring systems have been developed 
to optimize the use of clinical experience in cancer treatment. Our system tests the consistency 
between these scores while identifying risk categories, and the main procedure in this step is 
identifying whether conflict groups exist. During data pre-processing, prior knowledge is 
prepared for the analysis, and necessary prognostic factors are determined to implement previous 
prognostic scores. The data store contradiction in prior knowledge (validated prognostic scores) is 
prepared in this process. Feature ranking, conflict analysis and data normalization on a unified 
scale are performed to help in describing the relation between prognostic scores. 
 
Model development combines validated scoring systems to determine whether the combined 
model may further improve the prediction compared with a single source of knowledge. In this 
process, one needs to know what patients’ outcomes are as conveyed by previous prognostic 
scores. Using combined methods to resolve conflict in conflict groups adds another dimension of 
knowledge. Three levels are used for combining the validated prognostic scores and factors: 
combination, classification and feature. Prognostic factors are combined in the feature level,and 
prognostic scores are combined as score values and risk categories. Evaluating the combined 
methods and selecting the best approach can eliminate contradictions. Highest-accuracy methods 
will be selected for external evaluation. The final process is to use the selected prognostic models 
and validation on unseen data. Extending the prognostic model to adopt a new prognostic score or 
prognostic factor requires an additional process. Figure 2 shows the process flow. 
 
Figure2.Process flow of data mining processes used in prognostic model 
 
2.1.2 Predictive Model 
 
The predictive model also uses four data mining processes: problem understanding and data 
understanding, data pre-processing, model induction and post-processing. Figure 3 shows the 
process flow. The first process in knowledge discovery is divided into two stages. In the first 
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stage, each predictive factor used as an input parameter, studied to understand whether it is 
relevant to the prediction. When medical research data is reused, it is important to understand the 
data, such as the comprehensive treatment protocol or specifications for responses.Inclusion and 
exclusion criteria should also be decided before conducting any analysis to ensure that the 
material meets clinical requirements for the induction of a model with an accurate population.The 
second phase is data pre-processing. A statistical method is used to input missing values in 
predictive factors and prognostic scores from prior knowledge. Removing these patients is not an 
option in medical research data because most medical research data comprises small populations. 
For instance, patients who are enrolled in clinical trials mustprovide signed consent to undergo 
molecular targeted therapy in phase II clinical trials, as the safety profile of the drug is still not 
confirmed. Furthermore, we use domain knowledge to reformat the predictive factors. This 
process is performed before model induction by using medical knowledge to split continuous 
predictive factors into two or more linguistic terms and intervals. Thus, the clinical prediction 
rules can be interpretedmore easily based on domain concepts. 
 
Figure3.Process flow of data mining processes used in predictive model 
 
The third phase is model induction. First, there are three general steps for predictive model 
induction: training set, learning algorithm and performance evaluation on testing set. The training 
set represents the patient profiles that store the collected molecular, clinical and blood count 
information for individuals. We use available factors irrespective of whether we have prior 
knowledge that a factor’s ability to predict patient response has been identified or whether a 
factor is new in the field. This is because these factors will be used in feature selection techniques 
[58] to reduce the dimension of the data. Feature selection (predictive factor selection) is 
important to minimize the cost of the requested tests for a patient. In addition, technically, it can 
increase the model accuracy because removing unnecessary data may increase the quality of the 
training set [59]. The second step is the learning algorithm.This is an important step in which the 
selected machine learning techniques are used for learning [60]. The selected algorithm should 
outperform previous methods and should be interpretable. Interpretability is an important aspect 
for medical experts. The selected machine learning algorithm is popular in the medical domain as 
a primary analytical model for discovering the relation among variables, dividing a dataset into 
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groups based on shared characteristics (classification) and providing a set of clinical prediction 
rules that can be applied to new patients. The model performance is evaluated by comparing 
patients’ actual outcomes (molecular response) with those predicted by the model. A confusion 
matrix can help in measuring the performance based on accuracy, sensitivity, specificity, positive 
predictive value (PPV), negative predictive value (NPV), G-mean(geometric mean) and F-
score(weighted harmonic mean of sensitivity and PPV). Two sets are used in the model induction 
processfor validating a small dataset: training and testing setand cross-validation set[61]. When a 
dataset is divided into a number of equal folds, one fold is used for validation and the others, for 
training. The process is repeated to ensure that all folds are used one time for validation. The 
standard deviation is measured after completing this cross-validation approach. 
 
In post-processing, we compare the performance of the predictive models using validation sets 
and select the model that achieves the highest validation performance. The predictive model 
generates clinical prediction rules and discovers unknown knowledge by selecting relevant 
predictive factors (molecular tests, clinicalbase and cell count observations collected at diagnosis 
and categorized based on available knowledge) and extracting the relationship between the 
predictive factors and the molecular outcomes.This would prove that the approach could be 
applied in practice for treatment management by integrating domain knowledge in the learning 
process.A machine learning algorithm is used to discover unknown knowledge and perform 
classification. The predictive models present interesting properties of the data and use historical 
data to predict the behavior of unseen data. 
 
2.2 Prognostic and Predictive Factors 
 
The factors can be selected based on experts’ choices and publications. All predictive factors and 
prognostic factors have an equal chance of being studied by the selected feature selection 
techniques to compare the performance of each or group of predictive factors to predict the 
molecular response, and prognostic factors to allocate risk group. Many factors may influence the 
correlation between baseline data and end-point molecular response.There are manycategories of 
factors that maybe clinically based, biologically (molecularly) based, environmentally based, 
assay results and family history data etc. In a personalized medicine support system, we collect 
information from literature and create possible predictive and prognostic factors based on 
available data. We select the predictive and prognostic factors that include the patient’s individual 
information. For each patient݌𝑖ℎ𝑎ݏ ݌ ?݂? = {݌ ଵ݂, ݌݂ʹ, … , ݌݂𝑧}, where݌ ?݂? is the predictive and 
prognostic factors, z is the total number of factors, 𝑖 =  {ͳ, ʹ, ͵, … , ݊}is the number of patients 
and n is the total number of patients in dataset ܦ. Finally, ܦ contains rows of patient 𝑃𝑖and the 
columns are݌ ?݂?. Ideally, the predictive and prognostic values should have been previously studied 
and validated by using a group of patients with known responses to molecular targeted 
therapy.The following are possible factors that can be used as inputs for the system: 
 
 Clinical Factors: clinical factors are any specifications or measurements related to the 
patient, such as spleen size or agethat can be observed or obtained by clinicians. Clinical 
factors are collected on the day of diagnosis. 
 
 Biological Factors: patients are not biologically identical. Biological factors include 
blood cell counts or the activity levels of molecular parts. Multiple biological factors may 
influence the treatment response, and these may not be directly related to treatment 
outcomes. In practice, pathological tests are considered a primary pre-treatment step for 
individual patients. Including an individual’s information helps in realizing more specific 
treatment. In addition, currently, most interesting developments are related to real-time 
quantitative polymerase chain reaction (RQ-PCR) analysis for DNA sequences. To 
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monitor the molecular response, RQ-PCR, a sensitive technique, is used to quantify the 
level of mRNA transcripts in the peripheral blood of patients. 
 
 Predictive Assays: assays are used to predict possible outcomes following treatment [62]. 
Predictive assays can guide a clinician in making a rational choice of therapy at 
diagnosis. Identifying predictive assays, especially genetics-based ones, in a diverse 
group of individuals may provide substantial knowledge about the mechanisms of 
individual differences in responses to molecular targeted therapy.Groups whose assays 
show similar results can be treated similarly. Studying significant differences by the 
statistics of different thresholds for identifying groups of response and using a threshold 
less than a cut-off point (e.g. p< 0.5) are commonly used approaches in medical study. 
Here, we used a predefined threshold from publications and applied it to our dataset. 
 
2.3 Inclusion and Exclusion Criteria 
 
Inclusion criteria identify the base standard for including patient data in the study,and exclusion 
criteria exclude patient data based on predefined requirements. The reuse of medical research data 
requires refinement of patients in the secondary analysis. Inclusion and exclusion criteria help 
researchers in optimizing existing medical data to make it suitable for new research. In clinical 
trial data, patients adhere to research protocols and some standards. This clinical trial data usually 
uses information available for reuse in a second analysis if it first satisfies a new study’s inclusion 
and exclusion criteria. Understanding data is important to obtain accurate results and establish 
effective research. Building personalized medicine, as a predictive model to predict molecular 
responses to molecular targeted therapy should follow these criteria in the reuse of medical 
research data: 
 
 In clinical trials of molecular targeted therapy, patients from different trials must follow 
the same treatment protocol. 
 Molecular responses must be monitored according tointernational standards based on a 
pre-identified treatment guide. 
 Input data should be filtered at the diagnosis or pre-treatment stage. 
 Output prediction end-point should be identified. 
 If there is a disease phase, patients should be in the same phase or stage. 
 
Some clinical trials provide useful information by changing the values of some stored data under 
the guidance of human experts. For example, a patient group is switched to a second-line 
treatment during the trial. This group may have responded unsuccessfully to the frontline 
treatment and will therefore be defined as a negative responder to the selected treatment. 
 
The previous list of inclusion and exclusion criteria vary from study to study based on the specific 
research question under investigation and how much information can be analyzed from the 
existing resources by collaborating with the domain expert. 
 
2.4 Reformat using Domain Knowledge 
 
Defining the prognostic and predictive factors and reformatting them using domain knowledge is 
an important process as the final rules’ interpretability will be based on the earlier categories. We 
reformatted the factor values of text, numeral or mixed-type stored data by using existing 
knowledge such as standard boundaries of blood counts, domain knowledge of clinical expertise, 
risk categories and previous medical publications. Although some machine learning techniques 
can handle continuous predictor values, reformatting the data by categorizing each factor in the 
dataset into subgroups can help improve the comprehensibility of the final model. For each 
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predictive factor,we reformat the values of factors into categoryܥௗ,where݀ is the number of 
subcategories that represent values in the range using existing knowledge and confirmation by 
experts in the field.For example, we categorized the value of ݌݂ =  𝐼ܥͷͲ intofour categories,݀ = Ͷ: ܥଵ ≤  Ͳ.ͷμMasGroup 1, ܥଶ > Ͳ.ͷ 𝑎݊݀ ≤ Ͳ.7μMas Group 2, ܥଷ > Ͳ.7 𝑎݊݀ ≤ Ͳ.9ͷμMasGroup 
3 and ܥସ >  Ͳ.9ͷμMas Group 4. Then, we reformatted the index number of the category. If the 
final model selects a relevant predictive factor, we can use these categories to distinguish the 
predictive group on test patients. 
 
2.5 Modeling  
 
The framework is designed to deal with prior knowledge and extracting knowledge from a new 
source of data. Here, prognostic model used the prior knowledge that is collected from existing 
prognostic score systems while predictive model used medical data to extract knowledge in the 
form of clinical prediction rules.  
 
2.5.1 Dealing with Prior Knowledge (Prognostic Model) 
 
The development of the prognostic model was divided into two stages: (1) primary analysis and 
(2) combined model development.Figure 4. shows the schema for the prognostic model. In 
primary analysis, available prognostic factors, scores and models are surveyed.  
 
Figure 4.The schema for the prognostic model. 
 
An information matrix is created by adding the validated prognostic method in rows and columns 
representing the available information from each method. Primary analysis involves investigating 
the consistency between the prognostic methods by identifying the obtained risk outcomes using 
this prognostic method. Inconsistency occurs when two different risk categories are applied to the 
same patient,and it is observed that one prognostic score classifies the patient in one group and 
the other one contradicts the first classification. The consistency test can be briefly described as 
follows: 
 
1. Calculate the risk outcomes using prognostic factors included in the prognostic score 
equation (if available) for all patients in dataset D. 
Health Informatics - An International Journal (HIIJ) Vol.6, No.2, May 2017 
13 
2. Create dataset DPcontaining rows of patient 𝑃𝑖and the columns are𝑃ܵ𝑚, where 𝑃ܵ is 
the prognostic score methodsand ݉ the number of validated prognostic methods. 
3. Repeat step (1) for all ݉.  
4. Create an information matrix𝐼𝑀ଵfor risk outcomes from DP to identify the number of 
risk groups resulting from step (1) calculation. 
5. Analyze the risk categories obtained from𝐼𝑀ଵ, where ܴଵ is the minimum and ܴଶ is the 
maximum number of categories obtained from all prognostic methods. 
6. If ܴଵ is equal to ܴଶ, go to step (11). 
7. Combinedܴଶ risk groups to be equal to ܴଵ groups, where the groups can include all 
possible combinations of risk groups from ܴଶ. 
8. Evaluate the accuracy performance after combining risk groups. 
9. Select the combined risk group with the highest accuracy. 
10. Combine the risk categories to be equal toܴଵin the 𝑃ܵ𝑚that have more than ܴଵrisk 
groups. 
11. Test consistency in risk outcomes obtained from prognostic methods for each 𝑃𝑖 in DP. 
12. List in the information matrix 𝐼𝑀ଶthe possible combination of risk outcomes, which 
the number of rows is ܴଵ raised to𝑃ܵ𝑚. 
13. If 𝑃ܵଵ = 𝑃ܵଶ = … … 𝑃ܵ𝑚results have similar risk categories, 𝑃𝑖  is considered in a 
consistent risk group. However, if at least one 𝑃ܵ𝑚 has a different risk outcome for the 
same patient, 𝑃𝑖  is considered in a conflict group. 
 
Moving to the second stage of combining models, the steps briefly described as follows: 
 
1. In step (1), three possible data types could be generated: 
 
 DP1: risk categories set as categorical data type resulting from validated risk groups 
in prognostic model outcomes. 
 DP2: score values set as a continuous data type resulting from applying the equation 
used to calculate the score for the prognostic method. 
 DP3: prognostic factors (feature set) as both data types (categorical or continuous). 
 
Normalize DP2 and DP3: Normalization involves mapping the data values into the interval [0-1], 
where the minimum value is 0 and the maximum value, 1[63]. Normalization is an important 
process in this study for several reasons. First, the data from prognostic scores is usually not of 
the same scale. Grouping and comparing patients into logical descriptions using different 
intervalsin the problem space could make it difficult for the learning algorithm(especially the 
clustering base algorithm) to learn. Therefore, arranging the data into logical groups based on a 
unified scale among scores can help in describing the relation between risk groups. Second, for 
visualization, normalized prognostic score data is easy to represent in the space dimension. 
Finally, pre-processing real values into scaled values could help in finding a learning function 
from a space, such as finding the solution using the Euclidean distance between samples. 
 
2. Select the strategies to combinemodels (prognostic methods): model selection or model 
fusion[64]. 
 
 Model selection:Each model is supposed to be an expert in a specific domain of the 
feature space, and the selected model decides the output of the ensemble. 
 Model fusion: Each model is supposed to have complete information on the whole 
feature space, and we apply combiners to all outputs from the systems. 
 
3. The performance of single 𝑃ܵ𝑚 would be the same in model selection. Therefore, Select 
the classifier fusion method[64], and two possible combiner approach can be used: 
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 Non-trainable combiner (data-independent) such as majority voting. 
 Trainable combiner (data-dependent) methods can be used for building combinations. 
Here, we used common levels to combine models (prognostic scores) [64]: 
o Combination level:Mainly focuses on possible ways of combining the risk 
outputs of prognostic methods in an ensemble based on the information 
obtained from a single method. 
o Classifier level:Different machine learning techniques can be employed. 
o Feature level: Use patients’ prognostic factors for machine learning. 
 
4. Create a subset ܦ௖of conflict group of patients from DP as rows represent patient𝑃𝑖 and 
columns represent𝑃ܵ𝑚data. The last column is the actual molecular response𝑌𝑖: 
 𝑌𝑖= {Ͳ   ݊݋ݐ𝑎ܿℎ𝑖ݒ𝑖݊݃݉݋݈ܿݑ݈𝑎ݎݎ݁ݏ݌݋݊ݏ݁ͳ        𝑎ܿℎ𝑖ݒ݁𝑖݊݃݉݋݈ܿݑ݈𝑎ݎݎ݁ݏ݌݋݊ݏ݁ 
 
5. Divideܦ௖into training and testing datasets, and apply internal validation on training data. 
 
6. Create the combined prognostic model 𝑀௖specifically forܦ௖to classify𝑌𝑖 using different 
combined functions that maximize the accuracy of the classification. 
 
7. Evaluate the combined method by the combined function (classifier) by comparing the 
actual outcome 𝑌𝑖 withthe method outcome𝑌𝑖𝑀௖, and measure the model performance. 
 
8. Generate the evaluation datasetܧ, where the rows are all possible models𝑀௖that are built 
from different combined methods and the columns contain the performance 
measurements accuracy, sensitivity, specificity, PPV, NPV, G-mean and F-score. 
 
9. Rank the model 𝑀௖based on selected criteria. 
 
10. Select the best models𝑀௖that resolve the conflict. 
 
11. Evaluate the selected model 𝑀௖onall 𝑃𝑖in DP. 
 
12. Compare the performance of𝑀௖with the previous methods using testing data. 
 
13. Perform external validation on an unseen dataset. 
 
2.5.2 Dealing with a New Source of Clinical Data (Predictive Model) 
 
The schema for the predictive model is illustrated in Figure 5. Algorithms are often used to select 
a relevant subset of input features (in our problem, a subset of predictive factors that will deliver a 
highly predictive model)[59, 65].  
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Figure  5. The schema of the predictive model 
 
This is also very important in the context of healthcare costs, where fewer input factors imply 
fewer diagnostic tests to obtain the relevant predictive factors [66]. We also need to extract the 
relations between the most related predictive factors and try to understand whether there exist 
clinical rules for prediction. We divided the feature selection process into two main types: 
 
 A knowledge-driven method for feature selection, such as existing medical literature that 
has published predictive factors as an informative feature or clinical expert judgment on 
molecular factors associated with predicting molecular response, known as manual 
feature selection [67]. 
 Data-driven methods for feature selection, known as automatic feature selection. We used 
the wrapper approach [58], where all subsets of the features are evaluated using a given 
machine learning approach. 
 
Model induction can be briefly described as follows: 
 
1. Apply predictive factor𝑃 ?݂? selection on dataset ܦ to identify which predictive factors are 
important to be used as an input vector. 
2. Create sample 𝑥fromܦwhere rows represent patient 𝑃𝑖, and the columns are predictive 
factor𝑃 ?݂? . The last column is the actual molecular response𝑌𝑖: 
3. 𝑌𝑖= {Ͳ   ݊݋ݐ𝑎ܿℎ𝑖ݒ𝑖݊݃݉݋݈ܿݑ݈𝑎ݎݎ݁ݏ݌݋݊ݏ݁ͳ        𝑎ܿℎ𝑖ݒ݁𝑖݊݃݉݋݈ܿݑ݈𝑎ݎݎ݁ݏ݌݋݊ݏ݁ 
4. Divide 𝑥 into training and testing datasets, and apply internal validation to the training 
data. 
5. Create the predictive model𝑀𝑥specifically for𝑥to predict 𝑌𝑖 using the learning function 
that maximizes the predictionaccuracy. 
6. Evaluate the predictive factor subset by the learning function (classifier) by comparing 
the actual outcome 𝑌𝑖 withthe predicted outcomes𝑌𝑖𝑀𝑥 and measure the 
modelperformance. 
7. Generate the evaluation datasetܧ, where the rows are all possible models𝑀௖that are built 
from different combined methods and the columns contain the performance 
measurements accuracy, sensitivity, specificity, PPV, NPV, G-mean and F-score. 
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8. Rank the model based on selected criteria. 
9. Select the best models. 
10. Compare the performance of𝑀𝑥with the previous methods using testing data. 
11. Perform external validation on an unseen dataset. 
12. Visualize the structure of the model. 
13. Generate the clinical prediction rules. 
 
Clinicalprediction rules from data: in the clinical decision process, clinical prediction rules play 
an important role after increasing the acceptance of evidence-based medicine. This is because of 
the advantages that can be gained by using clinical prediction rules. First, these rules can support 
and guide clinicians in patient casesinvolving complex decisions. Second, these rules,which 
represent expert knowledge, can be shared with clinicians in primary care. Finally, these rules can 
be used to train and guide new experts.The decision tree structure represents extracted production 
rules [68]. We used the training set of patients from which a decision tree was generated to create 
a structure. The path from the root of the tree to the leaf node was used to establish the conditions 
(IF parts), whereas every leaf of a decision tree corresponded to a response (THEN parts). The 
decision rules R were in the form, IF 𝑃 ଵ݂is ܥଵ AND 𝑃 ଶ݂is ܥଶ , THEN Response is 𝑌, where 𝑃 ଵ݂and𝑃 ଶ݂  are the predictive factors, ܥଵ  and ܥଶ  are the subcategories that belong 
to 𝑃 ଵ݂and𝑃 ଶ݂,respectively, and 𝑌, is the class (molecular response achieved or not achieved). 
 
2.6 Evolving Approaches 
 
In a personalized medicine support system, there are three possible schemas for the evaluation of 
new knowledge: confirmation, contradiction and contribution [24]. In confirmation, no changes 
need to be made to the existing knowledge base. In contribution, the new knowledge is used for 
constructing predictive models and updating clinical prediction rules (predictive modeling steps 
in this study). In contradiction, the new knowledge conflicts with the old knowledge, and 
combined methods are used to resolve the conflict in knowledge (prognostic model steps in this 
study). 
 
The intelligent techniques used in the proposed framework are selected to generalize the 
predictive and prognosis performance. The predictive factor wrapper approach evaluates all 
possible combinations of predictive factors. Therefore, new predictive factors will be equally 
tested in the construction of predictive models. Prognostic modeling evaluates different 
combination levels. Therefore, a new level of knowledge, either prognostic factors, prognostic 
scores or prognostic model, can be combined and evaluated. Nested cross validation is a suitable 
validation method for evaluation, as internal validation can be used to evaluate the new 
knowledge and inform the decision of whether to enhance the performance, refine the modeling 
or ignore the new knowledge in case of no further improvement.The following suggestions are 
given as solutions and will be applied in a personalized medicine support system automatically if 
the internal validation of the selected model does not outperform a previous method in the unseen 
dataset (testing data).An evolving system can change in the following ways: 
 
 Data pre-processing phase in predictive model: the expert range of the predictive factors 
of conflict cases can be changed, and this should be confirmed by domain experts. 
 Predictive factor selection approaches: predictive factors or prognostic factors can be 
updated or added. 
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3. PROPOSED APPLICATIONS 
 
Personalized medicine support systems will provide great benefits in the future as molecular data 
analysis improves. This type of framework based on individual data will become a basic tool used 
by healthcare professionalsfor selecting personalized treatments. Clinicians will be able to 
allocate risk profiles and predict molecular responses to selected molecular targeted therapy, 
thereby improving treatment selection and avoiding disease progression. The treatment of many 
types of cancer can be explored using this framework. Table 1 shows some of the cancers that can 
be treated with multiple molecular targeted therapies as well as the available studies for 
prognostic and predictive factors. 
 
Table 1 of the cancers that can be treated with multiple molecular targeted therapies as well as the available 









Ado-trastuzumabemtansine (Kadcyla), Everolimus (Afinitor), 
Lapatinib (Tykerb), Palbociclib (Ibrance), Pertuzumab 
(Perjeta), Trastuzumab (Herceptin) 
[70] 
Lung cancer Afatinib (Gilotrif), Alectinib (Alecensa), Atezolizumab 
(Tecentriq), Ceritinib (Zykadia),Erlotinib (Tarceva), Gefitinib 
(Iressa), Necitumumab (Portrazza), Nivolumab (Opdivo), 
Osimertinib (Tagrisso), Pembrolizumab (Keytruda), 
Ramucirumab (Cyramza) 
[71] 
Melanoma Aldesleukin (Proleukin),Dabrafenib (Tafinlar),Ipilimumab 
(Yervoy), Nivolumab (Opdivo), Pembrolizumab (Keytruda), 





Imatinib (Gleevec), Nilotinib (Tasigna), Dasatinib (Sprycel), 
Ponatinib (Iclusig), Bosutinib (Bosulif) 




Alemtuzumab (Campath), Idelalisib (Zydelig), Obinutuzumab 
(Gazyva), Ofatumumab (Arzerra, HuMax-CD20), Rituximab 






The framework of current learning methodologies basically includesthe essential concept of 
dynamic changes in the input structure of models based on domain knowledge and discoveringthe 
relation of importance predictive factors with patient responses. In our framework, we conduct 
precise modeling based on prior knowledge with interpretable and consistent meanings,and we 
focus on developing models with high predictive and prognostic performance. 
 
Owing to space and time limitations, the implementation and some computational approaches 
have not been included in this paper. The initial future work is to implement a framework for real 
cancer patient data that stores molecular responses to molecular targeted therapy. Important areas 
for extending our proposed approach are as follows:(1) optimization techniques should be tested 
for model selection;(2) we trained models to maximize accuracy, but algorithms could also be 
developed to maximize the G-mean or F-score performance, especially in the imbalance 
dataset;(3) the use of a wider range of combined methods such as decision templates and the 
Dempster-Shafer method[76] should be enabled; and(4) online adaptive models that dynamically 
react to a new piece of knowledge should be developed. 
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In this paper, we have described a novel framework for a personalized medicine support system. 
A personalized medicine support system is a hybrid knowledge-based system that integrates 
multiple models to provide automated selection tools for individual treatment in one integrated 
dynamic environment. This system has been proposed to meet the requirements of clinicians and 
to provide a treatment guide. This system can work on oncology-based data using a data mining 
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